The nation of Zimbabwe has rejected a substantial US health deal worth 367 million US dollars (272 million pounds) over five years due to Washington's request for sensitive biological samples.
This move came to light following a internal memorandum dated December was disclosed, revealing that President Emmerson Mnangagwa felt the arrangement was "skewed".
An official spokesperson has since clarified that the United States was seeking biological samples for scientific study and commercial gain but refused to guarantee the resulting advantages from any future treatments.
"We are forced to start the challenging and unfortunate process of scaling back our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had donated more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has urged continued negotiations to secure a agreement acceptable to both sides so the nation's vital HIV programme can continue.
Wider Background
This development comes after a comparable case in neighbouring Kenya, where a high court blocked a similar health funding agreement following legal challenges were raised about the security of citizens' medical information.
After resuming the presidency last year, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
USAID had overseen assistance for the American government, but Trump argued its expenditure was "wasteful" and his government was seeking government-to-government agreements to enhance openness and responsibility.
Based on reports, Sixteen nations in Africa have so far agreed to similar health pacts, constituting over $18.3bn of fresh investment.
Specifics of the Declined Agreement
The money for Zimbabwe would have funded "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this cooperation would have delivered significant advantages for Zimbabwean communities, especially the 1.2 million presently receiving HIV treatment through American-funded initiatives," Tremont commented.
However, official spokesman Nick Mangwana said the arrangement was "asymmetrical".
"Zimbabwe was being asked to share its genetic material and health information for a long time, with no corresponding guarantee of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could result from that provided information," he stated.
"Put simply, our country would supply the raw materials for scientific discovery without any assurance that the end products would be accessible to our population should a new health crisis emerge."
Sovereignty and Global Health
He also said that the American exit from the global health body and its push of one-on-one health agreements were undermining systems already established through the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework designed to deal with potential global health emergencies.
"This system is intended to ensure that when a country contributes its information, the benefits – including medicines and cures – are distributed fairly, not monopolised solely by those with the funds to develop them."
The government's concerns regarding the US deal "should not be misconstrued as opposition to America," he added.
"We welcome ongoing discussions with our US partners on how future collaboration could be structured in a way that honours the sovereignty and dignity of both nations."
Medical Community Response
A leading public health body stated it acknowledged the official position, but urged that negotiations need to persist since much of the country's Aids initiatives relied on external financing.
"If specific concerns exist, such as those involving information security or implementation frameworks, these can frequently be addressed via detailed discussion and mutually agreed protections," it commented.
The situation underscores the complex debate between accepting vital international aid and protecting a country's data in an increasingly data-driven world.